Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care
Crossref DOI link: https://doi.org/10.1007/s12325-016-0412-8
Published Online: 2016-09-26
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Colivicchi, Furio
Gulizia, Michele Massimo
Franzini, Laura
Imperoli, Giuseppe
Castello, Lorenzo
Aiello, Alessandro
Ripellino, Claudio
Cataldo, Nazarena
Funding for this research was provided by:
AstraZeneca (IT)